Live Breaking News & Updates on Readiness for medical affairs communications teams summit

Stay informed with the latest breaking news from Readiness for medical affairs communications teams summit on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Readiness for medical affairs communications teams summit and stay connected to the pulse of your community

Sorry, Europe: AstraZeneca follows Pfizer/BioNTech in cutting back EU vaccine delivery plans

Jan 22, 2021 11:14am
AstraZeneca has reportedly notified EU officials of a reduction in expected first-quarter coronavirus vaccine deliveries. (AstraZeneca)
As AstraZeneca nears European authorization for its highly anticipated COVID-19 vaccine, the drugmaker has notified officials that initial shipments will come in lighter than originally expected.
Two German-language publications, Bild and oe24, report that AZ notified EU officials this week that its first-quarter deliveries will come in lower than originally expected. An AstraZeneca spokesperson attributed the dip to "reduced yields at a manufacturing site within our European supply chain."
"We will be supplying tens of millions of doses in February and March to the European Union, as we continue to ramp up production volumes," she said.

United-kingdom , British , Pfizer , Astrazeneca , Readiness-for-medical-affairs-communications-teams-summit , European-union , Launch-readiness , Medical-affairs , Communications-teams-summit , Covid-19 , Pharma

Eli Lilly's COVID-19 antibody shows it can prevent the disease. But will doctors use it?

Jan 22, 2021 10:55am
Eli Lilly said its antibody drug amlanivimab prevented symptomatic COVID-19 in nursing home residents and staffers. (GagliardiPhotography/Shutterstock)
Eli Lilly’s bamlanivimab was the first antibody drug the FDA authorized to treat COVID-19. Now, the Indianapolis pharma has data showing the therapy prevents symptomatic infections.
The catch? The data are limited to long-term care facilities, where vaccination is now underway—and despite their utility, antibody therapies are having a tough time catching on.
Bamlanivimab cut the risk of developing symptomatic COVID-19 by 57% among residents and staffers of long-term care facilities in a phase 3 trial conducted by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), Lilly said Thursday. The risk reduction was higher at 80% among the subgroup of nursing home residents.

China , Geoffrey-porges , Junshi-biosciences , Myron-cohen , Eli-lilly , Readiness-for-medical-affairs-communications-teams-summit , National-institute-of-allergy , Infectious-diseases , Launch-readiness , Medical-affairs , Communications-teams-summit , சீனா

Cognate beefs up cell, gene therapy manufacturing with new plants in U.S., EU

Jan 22, 2021 3:45pm
CDMO Cognate BioServices started work on a new commercial manufacturing plant that will nearly double capacity at its current headquarters in Memphis, Tennessee. (Cunaplus_M.Faba/iStock/Getty Images Plus)
With the demand for cell and gene therapies mounting, CDMO Cognate BioServices is looking to swiftly expand its U.S. headquarters with two new facilities—and it's not stopping there. Its dedicated gene therapy unit, Cobra Biologics, is plotting its own scale-ups in Europe.
Stateside, Cognate is building out its global manufacturing facility and headquarters in Memphis, Tennessee, to the tune of 250,000 square feet of space and 500 new jobs, which will be added over the next four years, a spokesperson said via email.

Boston , Massachusetts , United-states , Sweden , Tennessee , Matfors , Vasternorrland , Readiness-for-medical-affairs-communications-teams-summit , Centre-of-excellence , Fujifilm , Cobra-biologics

Remember normal? Pfizer and BioNTech join with health groups to remind us—and promote COVID-19 vaccine safety

Jan 21, 2021 10:25am
Pfizer and BioNTech join with health groups to promote “Science can make this possible. Only you can make it real,” COVID-19 awareness campaign.(Getty/Meyer & Meyer)
Remember hugging, playing with grandchildren, kissing people goodbye and sharing exciting news with family in person? While COVID-19 has kiboshed those things, Pfizer and BioNTech want to remind people about them—and how they'll be possible again with vaccines.
The Comirnaty vaccine makers, together with a coalition of health organizations, recently debuted an awareness campaign aimed at shoring up confidence in the new COVID-19 shots.
The 25- to 30-second videos are real takes of real people—found online and then licensed with consent for the digital campaign, which launched last week on social media. Future plans include a move to local TV.

United-states , American , Sharonj-castillo , Pfizer , Readiness-for-medical-affairs-communications-teams-summit , American-nurses-association , American-pharmacists-association , National-black-nurses-association , American-college-of-emergency-physicians , Launch-readiness , Medical-affairs

AstraZeneca, Daiichi Sankyo push Enhertu closer to the blockbuster frontier with stomach cancer OK

Daiichi Sankyo and partner AstraZeneca have taken their HER2-targeted cancer drug Enhertu another step toward blockbuster land. The FDA cleared the med for use in HER2-positive stomach cancer patients who previously received Roche’s standard-of-care Herceptin.

Japan , United-states , South-korea , Japanese , American , Daiichi-sankyo , Astrazeneca , Readiness-for-medical-affairs-communications-teams-summit , European-society-of-medical-oncology , American-society-of-clinical-oncology , Launch-readiness , Medical-affairs

Pfizer and BioNTech, scaling up for 2B coronavirus vaccine doses, temporarily cut deliveries in EU, Canada

Last week, Pfizer and BioNTech said they were boosting vaccine production to 2 billion doses this year. There's a catch, though: Scaling up a factory in Belgium to help meet that goal means supplies will run short temporarily.

Germany , Canada , Toronto , Ontario , Belgium , German , Doug-ford , Pfizer , Readiness-for-medical-affairs-communications-teams-summit , Health-christine-elliott , Reuters , Novartis

France, unions push Sanofi for no layoffs during cost-cutting drive: report

Sanofi CEO Paul Hudson’s restructuring plan for the French pharma includes almost 1,700 job cuts in Europe, but local government officials and employees aren't fans of the idea. As the French government pushes for no forced departures, some union members have taken to the streets.

France , Etoile , Rhôalpes , French , Paul-hudson , Bruno-le-maire , Readiness-for-medical-affairs-communications-teams-summit , Associated-press , Reuters , French-finance-minister-bruno-le-maire , Launch-readiness , Medical-affairs